
Regulatory tracker: Roche's Itovebi breast cancer regimen scores European approval
Welcome to Fierce Pharma's regulatory tracker for the second half of 2025. On this page, we're recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Be sure to come back regularly …